TGFB1 and Hepatic fibrosis: In animal models for liver fibrosis and pulmonary fibrosis, inhibition of the TGF-β pathway has been shown to have anti-fibrotic effects [4], [5], [6], reducing extracellular matrix deposition and pro-fibrotic cytokines.